Results 211 to 220 of about 3,554 (229)
Some of the next articles are maybe not open access.
Current opinion in investigational drugs (London, England : 2000), 2003
Pegvisomant, a polyethylene glycol (PEG) derivative of human growth hormone (GH) that acts as a highly selective GH receptor antagonist, is under development by Pharmacia (formerly Sensus) as a potential treatment for acromegaly. By February 2001, Sensus had submitted an NDA for the treatment of acromegaly, and an approvable letter indicating ...
Vincent, Goffin, Philippe, Touraine
openaire +1 more source
Pegvisomant, a polyethylene glycol (PEG) derivative of human growth hormone (GH) that acts as a highly selective GH receptor antagonist, is under development by Pharmacia (formerly Sensus) as a potential treatment for acromegaly. By February 2001, Sensus had submitted an NDA for the treatment of acromegaly, and an approvable letter indicating ...
Vincent, Goffin, Philippe, Touraine
openaire +1 more source
Current opinion in investigational drugs (London, England : 2000), 2004
Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH ...
Vincent, Goffin, Philippe, Touraine
openaire +1 more source
Pfizer (formerly Pharmacia), in collaboration with its wholly owned subsidiary Sensus, has developed and launched pegvisomant, a pegylated, genetically modified human growth hormone (hGH), for the treatment of acromegaly. Pegvisomant, in contrast to classical somatostatin analogs which lower hGH synthesis, exerts its anti-hGH action by preventing GH ...
Vincent, Goffin, Philippe, Touraine
openaire +1 more source
Growth hormone-receptor antagonist pegvisomant
DMW - Deutsche Medizinische Wochenschrift, 2004B L, Herrmann, C J, Strasburger
openaire +2 more sources